论文部分内容阅读
目的 探讨p53重组腺病毒 (Ad p53)与顺铂 (CDDP)或三氧化二砷 (As2 O3)联合应用提高膀胱癌疗效的可能性及其机制。方法 将Ad p53[1 0 0感染强度 (MOI) ]与CDDP(0 .5mg/L)或As2 O3(2 .0 μmol/L)联合应用 ,通过细胞生长抑制实验、克隆形成实验、细胞周期分析、免疫组织化学分析以及裸鼠皮下移植瘤模型 ,观察其对膀胱癌EJ细胞的作用及机制。结果 与单独应用相比 ,Ad p53与低剂量的CDDP或As2 O3联合可明显抑制EJ细胞体外生长 ,诱导EJ细胞凋亡 ,EJ细胞G2 /M期阻滞更明显 ;裸鼠体内肿瘤发生时间延迟 ,4周后肿瘤体积与单独应用时相比 ,差异有显著性 (P <0 .0 5)。结论 基因治疗与化疗联合应用 ,可进一步提高膀胱癌的疗效
Objective To investigate the possibility and mechanism of combined use of p53 recombinant adenovirus (Ad p53) and cisplatin (CDDP) or As2 O3 in the treatment of bladder cancer. Methods Ad p53 (MOI) was used in combination with CDDP (0.5mg / L) or As2O3 (2.0μmol / L). The cell growth inhibition, clonogenicity and cell cycle analysis , Immunohistochemical analysis and subcutaneous xenograft model in nude mice to observe its effect on bladder cancer EJ cells and its mechanism. Results Ad p53 combined with low dose of CDDP or As 2 O 3 could significantly inhibit the growth of EJ cells in vitro and induce the EJ cells apoptosis, and the G2 / M phase arrest in EJ cells was more obvious. The time of tumor in vivo was delayed After 4 weeks, the tumor volume was significantly different from that of the control group (P <0.05). Conclusions The combination of gene therapy and chemotherapy can further improve the curative effect of bladder cancer